These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
377 related articles for article (PubMed ID: 9759877)
1. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies. Mukherjee J; Kozel TR; Casadevall A J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877 [TBL] [Abstract][Full Text] [Related]
2. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943 [TBL] [Abstract][Full Text] [Related]
3. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. Feldmesser M; Casadevall A J Immunol; 1997 Jan; 158(2):790-9. PubMed ID: 8992996 [TBL] [Abstract][Full Text] [Related]
4. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide. Valadon P; Nussbaum G; Oh J; Scharff MD J Immunol; 1998 Aug; 161(4):1829-36. PubMed ID: 9712050 [TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies. Cleare W; Cherniak R; Casadevall A Infect Immun; 1999 Jun; 67(6):3096-107. PubMed ID: 10338526 [TBL] [Abstract][Full Text] [Related]
6. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library. Beenhouwer DO; May RJ; Valadon P; Scharff MD J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134 [TBL] [Abstract][Full Text] [Related]
7. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan. Duro RM; Netski D; Thorkildson P; Kozel TR Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451 [TBL] [Abstract][Full Text] [Related]
8. [Monoclonal antibodies recognizing the capsular polysaccharide of Cryptococcus neoformans]. Rodríguez Sánchez H; Pupo Antúnez M; Ilnait MT; Otero A; Martínez Machín G Rev Cubana Med Trop; 2005; 57(2):162-4. PubMed ID: 17966590 [TBL] [Abstract][Full Text] [Related]
9. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327 [TBL] [Abstract][Full Text] [Related]
10. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Casadevall A; DeShaw M; Fan M; Dromer F; Kozel TR; Pirofski LA Infect Immun; 1994 Sep; 62(9):3864-72. PubMed ID: 8063403 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan. Maitta RW; Datta K; Pirofski LA Vaccine; 2004 Sep; 22(29-30):4062-8. PubMed ID: 15364457 [TBL] [Abstract][Full Text] [Related]
12. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection. Fleuridor R; Lees A; Pirofski L J Immunol; 2001 Jan; 166(2):1087-96. PubMed ID: 11145689 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Mukherjee J; Zuckier LS; Scharff MD; Casadevall A Antimicrob Agents Chemother; 1994 Mar; 38(3):580-7. PubMed ID: 8203858 [TBL] [Abstract][Full Text] [Related]
15. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity. Netski D; Kozel TR Infect Immun; 2002 Jun; 70(6):2812-9. PubMed ID: 12010967 [TBL] [Abstract][Full Text] [Related]
16. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223 [TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans. Brandt S; Thorkildson P; Kozel TR Clin Diagn Lab Immunol; 2003 Sep; 10(5):903-9. PubMed ID: 12965925 [TBL] [Abstract][Full Text] [Related]
18. Unexpected diversity in the fine specificity of monoclonal antibodies that use the same V region gene to glucuronoxylomannan of Cryptococcus neoformans. McFadden DC; Casadevall A J Immunol; 2004 Mar; 172(6):3670-7. PubMed ID: 15004170 [TBL] [Abstract][Full Text] [Related]
19. Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans. Todaro-Luck F; White EH; Reiss E; Cherniak R Mol Cell Probes; 1989 Dec; 3(4):345-61. PubMed ID: 2482437 [TBL] [Abstract][Full Text] [Related]
20. Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. Yuan R; Casadevall A; Spira G; Scharff MD J Immunol; 1995 Feb; 154(4):1810-6. PubMed ID: 7836766 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]